[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-33113":3,"doc-seo-33113":27},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"file_id":15,"file_url":16,"file_type":17,"file_size":18,"view_count":4,"is_deleted":4,"is_public":19,"is_downloadable":19,"audit_status":19,"page_count":20,"language":21,"language_code":22,"table_of_contents":23,"faqs":24,"seo_title":13,"seo_description":14,"update_tm":25,"read_time":26},33113,3848291630094,"Emma Wilson","https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45",7,"Healthcare","Reversal of Cognitive Decline in Alzheimer’s Disease","Alzheimer’s disease is a major global healthcare challenge, and earlier reports described reversal of cognitive decline in patients with early Alzheimer’s disease or its precursors. The therapeutic strategy used a programmatic, personalized approach called metabolic enhancement for neurodegeneration (MEND) rather than a single fixed monotherapy. Follow-up results combine quantitative MRI and neuropsychological testing in ten patients treated for 5–24 months. Marked functional and cognitive improvements were reported across ApoE4+ and one ApoE4− participant, with objective evidence supporting strong efficacy and broad implications for MCI and SCI treatment.","cbCaitNFaVv4c6YQ","https://ap.wps.com/l/cbCaitNFaVv4c6YQ","pdf",456028,1,9,"English","en","# Introduction\n# Results\n## Case studies","[{\"question\":\"What treatment approach is used in this study for cognitive decline in Alzheimer’s disease and related conditions?\",\"answer\":\"The study uses metabolic enhancement for neurodegeneration (MEND), a programmatic and personalized approach rather than a monotherapeutic, invariant treatment.\"},{\"question\":\"How many patients were treated, and for how long?\",\"answer\":\"Ten patients with cognitive decline were treated with the MEND protocol for 5–24 months.\"},{\"question\":\"What objective measures were used to evaluate changes after treatment?\",\"answer\":\"The study reports results from quantitative MRI and neuropsychological testing, including biomarkers and imaging findings such as amyloid-PET and FDG-PET.\"}]",1782202949,23,{"code":4,"msg":28,"data":29},"ok",{"site_id":30,"language":22,"slug":31,"title":13,"keywords":32,"description":14,"schema_data":33,"social_meta":84,"head_meta":86,"extra_data":88,"updated_unix":25},105,"reversal-of-cognitive-decline-in-alzheimers-disease","",{"@graph":34,"@context":83},[35,52,66],{"@type":36,"itemListElement":37},"BreadcrumbList",[38,42,46,49],{"item":39,"name":40,"@type":41,"position":19},"https://docshare.wps.com","Home","ListItem",{"item":43,"name":44,"@type":41,"position":45},"https://docshare.wps.com/document/","Document",2,{"item":47,"name":12,"@type":41,"position":48},"https://docshare.wps.com/document/healthcare/",3,{"item":50,"name":13,"@type":41,"position":51},"https://docshare.wps.com/document/reversal-of-cognitive-decline-in-alzheimers-disease/33113/",4,{"url":50,"name":13,"@type":53,"author":54,"headline":13,"publisher":56,"fileFormat":59,"description":14,"dateModified":60,"datePublished":60,"encodingFormat":59,"isAccessibleForFree":61,"interactionStatistic":62},"DigitalDocument",{"name":9,"@type":55},"Person",{"url":39,"name":57,"@type":58},"DocShare","Organization","application/pdf","2026-06-23",true,{"@type":63,"interactionType":64,"userInteractionCount":4},"InteractionCounter",{"@type":65},"ViewAction",{"@type":67,"mainEntity":68},"FAQPage",[69,75,79],{"name":70,"@type":71,"acceptedAnswer":72},"What treatment approach is used in this study for cognitive decline in Alzheimer’s disease and related conditions?","Question",{"text":73,"@type":74},"The study uses metabolic enhancement for neurodegeneration (MEND), a programmatic and personalized approach rather than a monotherapeutic, invariant treatment.","Answer",{"name":76,"@type":71,"acceptedAnswer":77},"How many patients were treated, and for how long?",{"text":78,"@type":74},"Ten patients with cognitive decline were treated with the MEND protocol for 5–24 months.",{"name":80,"@type":71,"acceptedAnswer":81},"What objective measures were used to evaluate changes after treatment?",{"text":82,"@type":74},"The study reports results from quantitative MRI and neuropsychological testing, including biomarkers and imaging findings such as amyloid-PET and FDG-PET.","https://schema.org",{"og:url":50,"og:type":85,"og:title":13,"og:site_name":57,"og:description":14},"article",{"robots":87,"canonical":50},"index,follow",{"doc_id":7,"site_id":30}]